Dupilumab + Placebo

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Lichen Simplex Chronicus

Conditions

Lichen Simplex Chronicus

Trial Timeline

Nov 28, 2024 → Aug 31, 2026

NCT ID

NCT06687967

About Dupilumab + Placebo

Dupilumab + Placebo is a phase 3 stage product being developed by Sanofi for Lichen Simplex Chronicus. The current trial status is active. This product is registered under clinical trial identifier NCT06687967. Target conditions include Lichen Simplex Chronicus.

What happened to similar drugs?

0 of 1 similar drugs in Lichen Simplex Chronicus were approved

Approved (0) Terminated (0) Active (1)

🔄Dupilumab + PlaceboSanofiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07053423	Approved	Recruiting	Sep 22, 2025	Feb 15, 2029	Chronic Obstructive Pulmonary Disease
NCT06687967	Phase 3	Active	Nov 28, 2024	Aug 31, 2026	Lichen Simplex Chronicus
NCT06687980	Phase 3	Active	Nov 25, 2024	Aug 31, 2026	Lichen Simplex Chronicus
NCT06191315	Phase 3	Recruiting	Jan 3, 2024	Dec 21, 2028	Wheezing
NCT06101095	Approved	Active	Nov 29, 2023	Feb 1, 2028	Eosinophilic Oesophagitis
NCT05731128	Phase 2	Active	Jan 12, 2023	Feb 19, 2027	Colitis Ulcerative
NCT05097287	Approved	Recruiting	Dec 16, 2021	Aug 21, 2029	Asthma
NCT04988022	Approved	Completed	May 25, 2021	Mar 24, 2025	Keloid
NCT04417894	Phase 3	Completed	Apr 14, 2021	Nov 23, 2022	Moderate to Severe Atopic Hand and Foot Dermatitis
NCT04442269	Phase 2	Completed	Sep 15, 2020	Feb 9, 2024	Allergic Bronchopulmonary Aspergillosis
NCT04512339	Phase 2	UNKNOWN	Aug 1, 2020	Aug 1, 2022	Hand Eczema
NCT04400318	Approved	Completed	Jun 20, 2020	Aug 21, 2023	Asthma
NCT04033367	Approved	Completed	Aug 22, 2019	Oct 6, 2021	Atopic Dermatitis
NCT03749148	Phase 2	Completed	Dec 10, 2018	Feb 28, 2023	Cholinergic Urticaria
NCT03749135	Phase 2	Completed	Nov 12, 2018	Jul 7, 2021	Chronic Spontaneous Urticaria
NCT03633617	Phase 3	Completed	Sep 24, 2018	Jun 7, 2022	Eosinophilic Esophagitis
NCT03389893	Approved	Terminated	Jul 25, 2018	Sep 9, 2020	Atopic Dermatitis (AD)
NCT03359356	Phase 2	Completed	Jan 9, 2018	Dec 17, 2020	Alopecia Areata
NCT03054428	Phase 3	Completed	Mar 21, 2017	Jun 5, 2018	Moderate-to-Severe Atopic Dermatitis
NCT02379052	Phase 2	Completed	May 12, 2015	Jul 10, 2017	Eosinophilic Esophagitis

Competing Products

12 competing products in Lichen Simplex Chronicus

See all competitors

Product	Company	Stage	Hype Score
LP-10 (Liposomal Tacrolimus)	Lipella Pharmaceuticals	Phase 2	29
Tacrolimus cream + Clobetasol cream	Astellas Pharma	Phase 2	35
Baricitinib 4 milligram Oral Tablet	Eli Lilly	Phase 2	39
pimecrolimus and clobetasol + clobetasol 0.05% cream	Novartis	Phase 2	35
Pimecrolimus 1% cream	Novartis	Phase 2	35
secukinumab 300 mg Q4W + secukinumab 300 mg Q2W	Novartis	Phase 2	35
Apremilast + Placebo	Amgen	Phase 2	31
Deucravacitinib	Bristol Myers Squibb	Phase 2	35
Dupilumab + Placebo	Sanofi	Phase 3	44
Amevive (Alefacept) + Placebo	Biogen	Phase 2	24
Ruxolitinib cream + Vehicle cream	Incyte	Phase 2	32
Ruxolitinib cream + Vehicle cream	Incyte	Phase 2	32